Equities

Aldeyra Therapeutics Inc

Aldeyra Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)5.52
  • Today's Change0.18 / 3.37%
  • Shares traded337.79k
  • 1 Year change+111.49%
  • Beta1.3726
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.

  • Revenue in USD (TTM)0.00
  • Net income in USD-37.87m
  • Incorporated2004
  • Employees10.00
  • Location
    Aldeyra Therapeutics Inc131 HARTWELL AVENUE, SUITE 320LEXINGTON 02421United StatesUSA
  • Phone+1 (781) 761-4904
  • Fax+1 (302) 636-5454
  • Websitehttps://www.aldeyra.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Poseida Therapeutics Inc88.46m-112.77m299.13m337.00--4.92--3.38-1.19-1.190.92960.62650.3051--7.27268,066.70-38.89-40.70-52.75-47.72-----127.48-233.49---13.140.4916---50.42---92.85--19.01--
Vanda Pharmaceuticals Inc.190.86m-16.39m302.52m203.00--0.559--1.59-0.2824-0.28243.299.290.29679.305.30940,187.20-2.556.61-2.957.6293.6290.55-8.5915.184.84----0.00-24.27-0.0496-60.02-36.96-56.77--
Tscan Therapeutics Inc12.20m-104.41m306.19m175.00--1.20--25.10-1.05-1.050.12254.820.0353----79,220.78-30.19---33.78-------855.84------0.1066--55.52---34.73------
Taysha Gene Therapies Inc12.87m-114.34m307.41m52.00--2.77--23.88-0.8987-0.89870.06430.54060.0913----247,557.70-81.11---116.01-------888.18------0.2598--517.55--32.80------
AVITA Medical Inc60.04m-57.32m310.58m207.00--25.62--5.17-2.23-2.232.330.46640.74091.537.30290,048.30-70.74---86.14--86.46---95.47--3.37-11.270.7768--45.68---32.69------
Nautilus Biotechnology Inc0.00-70.21m312.65m161.00--1.40-----0.561-0.5610.001.780.00----0.00-24.29---25.05--------------0.00-------9.93------
Mersana Therapeutics Inc29.94m-104.77m315.27m123.00--37.41--10.53-0.8648-0.86480.24690.06870.1222--38.14243,390.30-42.75-61.68-59.36-81.35-----349.98-622.19----0.7508--38.6528.3215.94--9.61--
AC Immune SA17.69m-69.13m316.61m133.00--2.25--17.89-0.7332-0.73320.19111.420.0787--28.76133,041.40-30.73-18.25-42.90-19.52-----390.68-148.29---128.010.0255--276.1415.5223.35---15.49--
Tango Therapeutics Inc43.38m-123.40m316.88m140.00--1.38--7.30-1.15-1.150.40412.130.1112----309,885.70-31.62---35.28-------284.43------0.00--46.93--5.95------
Artiva Biotherapeutics Inc-100.00bn-100.00bn318.40m82.00--------------1.09----------------------------0.0087--579.21--51.15------
Rezolute Inc0.00-68.46m323.32m59.00--2.46-----1.33-1.330.002.270.00----0.00-53.39-50.36-56.66-53.25------------0.00-------32.19------
Aldeyra Therapeutics Inc0.00-37.87m328.01m10.00--3.34-----0.6387-0.63870.001.650.00----0.00-26.89-36.79-31.76-40.77------------0.1342------39.47------
Design Therapeutics Inc0.00-50.53m330.10m57.00--1.26-----0.8982-0.89820.004.610.00----0.00-17.39---17.96--------------0.00-------5.61------
Codexis Inc64.45m-62.09m332.02m174.00--4.52--5.15-0.878-0.8780.91490.9020.42597.033.62370,379.30-41.03-17.13-54.21-20.2375.9677.29-96.35-37.043.15--0.2806---49.392.97-126.96--9.80--
iTeos Therapeutics Inc35.00m-108.14m338.56m157.00--0.51--9.67-3.00-3.000.951718.180.0481--1.52222,929.90-14.865.84-15.557.02-----308.9622.09----0.000.00-95.29---216.54--68.45--
enGene Holdings Inc0.00-123.44m349.30m33.00--1.52-----4.77-4.770.005.210.00----0.00-78.13---84.20-------------3.140.0906-------260.87------
Data as of Nov 08 2024. Currency figures normalised to Aldeyra Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

46.10%Per cent of shares held by top holders
HolderShares% Held
Perceptive Advisors LLCas of 30 Jun 20249.28m15.61%
Knoll Capital Management LPas of 30 Jun 20245.48m9.22%
The Vanguard Group, Inc.as of 30 Jun 20243.70m6.22%
BlackRock Fund Advisorsas of 30 Jun 20243.33m5.60%
Kennedy Capital Management LLCas of 30 Jun 20241.60m2.69%
Geode Capital Management LLCas of 30 Jun 20241.14m1.92%
SSgA Funds Management, Inc.as of 30 Jun 2024957.72k1.61%
Eagle Asset Management, Inc.as of 30 Jun 2024841.57k1.42%
Dimensional Fund Advisors LPas of 30 Sep 2024551.12k0.93%
Federated MDTA LLCas of 30 Jun 2024531.22k0.89%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.